The Supervisory Board and Executive Board today resolved to propose a dividend of EUR 0.50 per dividend bearing share to the Annual General Meeting.

The Executive Board anticipates significant sales and earnings growth for the 2024 financial year. In the Beauty segment, it expects sales of EUR 80 to 90 million (financial year 2023: EUR 70.8 million) and earnings before interest and taxes (EBIT) of EUR 18 to 22 million (financial year 2023: EUR 15.5 million). The 2023 annual report of M1 Kliniken AG is expected to be published on published on 23 May 2024.

About M1 Kliniken AG
M1 Kliniken AG is the leading fully integrated provider of aesthetic medical healthcare services in Europe. The Group offers products and services of the highest quality standards in the aesthetic and surgical fields. Beauty medical treatments are currently offered at 61 specialist centres under the “M1 Med Beauty” brand. With six operating rooms and 35 beds, the “M1 Schlossklinik” for Plastic and Aesthetic Surgery in Berlin is one of the largest and most modern facilities of its kind in Europe. M1 Kliniken has been driving forward its internationalisation since the end of 2018 and is currently represented in ten countries.

Contact:
Attila Strauss (Co-CEO), Kilian Brenske (Co-CEO)
Corporate Communications
E-Mail: ir@m1-kliniken.de

MPH Health Care AG: Supervisory Board adopts the 2023 annual financial statements. Dividend proposal of EUR 1.20 per share

Berlin, 07.05.2024 – At its balance sheet meeting today, the Supervisory Board of MPH Health Care AG (ISIN: DE000A289V03) approved the annual financial statements and the consolidated financial statements of the company for the 2023 financial year submitted by the Management Board in accordance with Sections 171 and 172 AktG. The annual financial statements are thus adopted in accordance with Section 172 AktG.

The Supervisory Board and Management Board today resolved to propose a dividend of EUR 1.20 per dividend-bearing share to the Annual General Meeting.

The 2023 Annual Report of MPH Health Care AG is expected to be published on 30 May 2024.

About MPH Health Care AG:

MPH AG is an investment company with a strategic focus on the acquisition, development and sale of companies and company shares, particularly in growth segments of the healthcare market. This includes both insurance-financed and privately financed segments. But MPH also exploits potential from high-growth and high-return sectors outside the healthcare market.

Contact:
Patrick Brenske, Management Board
Corporate Communications
E-Mail: ir@mph-ag.de

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82%

BERKELEY, US – MAINZ, Germany – May 7, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will present  an analysis from  its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in Washington D.C. from May 18th to May 21^st. DDW is recognized as a premier forum for the latest advancements in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

eAArly DETECT is a US multi-site study performed at 21 specialized gastroenterology sites that enrolled 254 clinical patients . The results show compelling performance of its multimodal screening test combining Fecal Immunochemical Test (FIT), DNA and mRNA biomarkers with a unique artificial intelligence (AI) / machine learning algorithm to differentiate between colorectal cancer (CRC), advanced adenomas (AA), non-advanced adenomas and patient samples with no findings.

The presentation will delve into the test’s ability to accurately analyze a combination of biomarkers, improving early detection rates for both colorectal cancer and significant precancerous conditions. By leveraging this dual approach, Mainz Biomed aims to accelerate the shift from cancer detection to prevention by advancing current colorectal cancer screening practices, reflecting its commitment to reducing cancer mortality rates worldwide.

Presentation Details

Session Title: Cancer, Early Detection, Biomarkers for Diagnosis, Treatment and Prognosis of GI Cancers
Session Sponsor: AGA
Title:  “NOVEL STOOL-BASED NON-INVASIVE EARLY DETECTION OF COLORECTAL CANCER AND PRECANCEROUS LESIONS BY CLASSIC FIT COMBINED WITH NUCLEIC ACID-BASED BIOMARKER SIGNATURES.”
Presenter: Kammers, L
Session: Sunday May 19, 2024, from 12:30 PM to 1:30 PM EDT
Poster #: Su1117
Key findings: First analysis of the eAArly DETECT clinical study reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82%. Resulting performance data confirms that this multimodal screening strategy reflects a substantial and meaningful improvement for CRC and especially AA detection, where improved sensitivity is urgently needed to decrease CRC incidence and mortality.

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information.

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook 

About eAArly DETECT

eAArly DETECT was performed to identify novel mRNA biomarkers for potential integration into the Mainz Biomed’s pivotal FDA PMA clinical trial ReconAAsense. The study enrolled 254 evaluable subjects across 21 sites in the U.S. with a similar design to that of ColoFuture, its European counterpart. Patients aged 45 years and older were invited to participate when referred for a colonoscopy to either screen for CRC (average risk), to follow up on a positive non-invasive test, imaging or symptoms, or if a subject was already identified as having colorectal cancer but before any treatment had been administered. Those who agreed to provide a stool sample in advance of the colonoscopy (or treatment in the case of subjects with already identified colorectal cancer) were eligible for participation. Subjects were classified into groups following central pathology review: CRC, advanced adenoma, non-advanced adenoma, no findings, or non-colorectal cancer. Each subject outcome was compared to the results from the ColoAlert^® test incorporating the novel biomarkers.

About ColoAlert®

ColoAlert®, Mainz Biomed’s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert® detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Dollinger et al., 2018, Franck et al. 2024). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert® will be evaluated in the FDA-registration trial ‘ReconAAsense.’ Once approved in the US, the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.

About Colorectal Cancer

Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert® should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market opportunity in the US.

About Mainz Biomed N.V.  

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert® is currently marketed across Europe. The Company is planning to run a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com.   

For media inquiries

MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu  

For investor inquiries, please contact info@mainzbiomed.com

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Press release // 07 May 2024

Formycon invites to the Annual General Meeting on June 12, 2024 in Munich

• Formycon proposes to the Annual General Meeting a more international focus and expansion of the Supervisory Board to five members
• With Colin Bond, Dr. Bodo Coldewey and Nicholas Haggar, three new candidates with relevant industry and financial expertise stand for election
• Dr. Olaf Stiller and Peter Wendeln to step down from the Supervisory Board by mutual agreement

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) has published the invitation to its Annual General Meeting on Wednesday, June 12, 2024. The Annual General Meeting will be held as an in-person event for shareholders and their proxies from 11 a.m. (CEST) at the Haus der Bayerischen Wirtschaft in Munich.

The agenda for this year’s Annual General Meeting includes proposed resolutions for the election of two new members to the Supervisory Board, an increase in the size of the Supervisory Board from four to a total of five members and the election of a new member to the expanded Supervisory Board. The aim is to achieve a more international focus and expand the industrial and financial expertise of the Supervisory Board with new independent members.

In agreement with Formycon, the Chairman of the Supervisory Board, Dr. Olaf Stiller, and his Deputy, Peter Wendeln, have decided to resign from the Supervisory Board after more than 10 years of service with effect from the end of the Annual General Meeting on June 12, 2024. 

The Executive Board of Formycon AG therefore proposes to the Annual General Meeting that a total of three new members be elected to the Supervisory Board. Dr. Bodo Coldewey, Managing Director of WEGA Invest GmbH, the family office of the Wendeln family, and Nicholas Haggar, currently CEO of healthqube Ltd and long-standing executive at major pharmaceutical companies, are standing for election to replace the outgoing members. Colin Bond, currently CFO of Sandoz Group AG, will be proposed as a new member of the expanded Supervisory Board effective 1 October 2024.

The previously elected Supervisory Board members Wolfgang Essler, General Authorized Representative of ATHOS KG, and Klaus Roehrig, Founding Partner of the Active Ownership Group AOC, will continue their duties. Wolfgang Essler has agreed to take over as Chairman of the Supervisory Board following the election of the new Supervisory Board by the Annual General Meeting. 

Dr. Olaf Stiller, Acting Chairman of the Supervisory Board, commented on his decision to support and initiate the more international approach and the expansion of the Supervisory Board: “Formycon has made impressive progress in recent years and is on track for expansion with a growing and sustainable biosimilar pipeline. Now, it is the right time to pass the baton to new hands. I co-founded the company, have actively supported it for a long time and will remain closely associated with it as I am very proud of this great company with its experienced and strong team”. 

Peter Wendeln, Deputy Chairman of the Supervisory Board, said: “As an investor from the very beginning and today Formycon’ s second largest shareholder, I am very interested in ensuring that the path we have taken, and the greater internationalization of the business are successful. In addition to strong partners in manufacturing and commercialization, it is important to have an internationally focused management and Supervisory Board team with a strong sector network and financial expertise, and to adapt and strengthen this team in line with the company’s development. Like Dr. Olaf Stiller, I will remain closely associated with Formycon and proudly follow its further development.”

Stefan Glombitza, CEO of Formycon AG, commented: “The biosimilars market will grow rapidly in the coming years. The development and commercialization of biosimilars will enable us to achieve our mission of providing high-quality medicines. The entire Management Board of Formycon AG and its employees are extremely committed to this task and are working with great passion to lead Formycon into a promising and profitable future. We would like to thank Dr. Olaf Stiller and Peter Wendeln from the bottom of our hearts for their tireless commitment to Formycon as Supervisory Board members, for their strategic vision as investors and for the great support that my colleagues and I have received over the years. As Management, we welcome the new suggestions for the Supervisory Board and its expansion to five members and hope for the approval of our Annual General Meeting.”

On June 12, 2024, the following candidates will stand for election by the shareholders:

Colin Bond

Colin Bond is currently CFO of Sandoz Group AG, Basel, Switzerland and will retire from Sandoz on June 30, 2024. Before joining Sandoz, he was CFO of Vifor Pharma from 2016 to 2022 and prior to that CFO of Evotec AG from 2010 to 2016. During his early career, he worked as a pharmacist, auditor, and management consultant for Procter & Gamble, Arthur Andersen, and PricewaterhouseCoopers LLP, respectively. His academic background includes a BSc. in Pharmacy and an MBA degree from London Business School. He is a fellow of the Institute of Chartered Accountants in England and Wales and a member of the Royal Pharmaceutical Society. Colin Bond holds dual British and Swiss citizenship.  

Dr. Bodo Coldewey

Dr. Bodo Coldewey is Managing Director of WEGA Invest GmbH, the family office of the Wendeln family, and has extensive experience in corporate management and investments. He plays a central role in the strategic direction and management of significant assets of the family office. Prior to his time at WEGA Invest, Dr. Coldewey held senior positions in the banking, investment and consulting sectors. He therefore brings not only the necessary financial expertise, but also a valuable entrepreneurial perspective to the Supervisory Board.

“The Family Office Wendeln has accompanied Formycon for many years and it would be a great pleasure for me to take over the mandate from Peter Wendeln, who would like to retire from operational Supervisory Board work, and to be able to support this rising company with my expertise as it continues to grow.” 

Nicholas Haggar

Nicholas Haggar is a British citizen and CEO of healthqube ltd, Berkhamsted, UK, a venture capital investment firm focused on pharmaceutical and biotechnology companies. Investments focus on specialty, biologics and innovative medicines. He has gained extensive experience in the biopharmaceutical industry and held executive positions in renowned pharmaceutical companies such as GSK, Sandoz and Zentiva over the last 30 years. His broad skills in corporate development and his commitment to the development of biosimilars make him a valuable leader in the industry.

“Formycon is already one of the most successful pure-play biosimilar developers with an excellent international reputation. I would like to bring my many years of experience in this emerging market segment to the company and contribute to the further development of Formycon.”

Further information:

The invitation for the Annual General Meeting and further voluntary information on the candidates proposed for election, including information on memberships in statutory supervisory boards and comparable domestic and foreign supervisory bodies, are available on the company’s website at https://www.formycon.com/en/investor-relations/annual-general-meeting-2024/.

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/Ranibizumab, Formycon already has a biosimilar on the market in Europe and the USA. Another five biosimilar candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines. Formycon AG is headquartered in Munich and is listed on the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: https://www.formycon.com

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare providers. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Contact:
Sabrina Müller,
Director Investor Relations & Corporate Communications,
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

Tel.: +49 (0) 89 – 86 46 67 149
Fax: + 49 (0) 89 – 86 46 67 110
Sabrina.Mueller@formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.

PRESS RELEASE

Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024

• Product sales increased by 17.7% to Euro 138.0 million
• EBIT increased to Euro 52.8 million
• Successful completion Fibrinogen study

Dreieich, 07 May 2024. The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 2024 financial year. This represents an increase of 83.6 % compared to revenue of € 117.2 million in the same period of the previous year.

Product sales increased by 17.7 % to € 138.0 million. Additionally, revenue due to sales from technology disclosure and development services for Grifols, S.A. as part of the technology transfer and licensing agreement amounted to
€ 77.2 million.

The new intravenous immunoglobulin Yimmugo^® had a positive impact with an increase in sales of € 7.5 million to € 11.1 million, which was successfully launched on the market in November 2022 and is now the first commercial preparation to be manufactured in an innovative production process at the new Biotest Next Level production facility at the Dreieich site in Germany. Intratect^® also contributed to the increase in sales.

EBIT for the first quarter of 2024 amounted to € 52.8 million, a significant improvement on the first quarter of the previous year (prior year period: € – 9.1 million). This includes expenses of € 22.9 million for the ramp-up of production capacity at the Biotest Next Level facility (prior year period: € 22.2 million). The improvement in EBIT is mainly due to the earnings effect from technology disclosure and development services for Grifols, S.A. amounting to € 70.3 million.

The financial result for the first quarter of the current year deteriorated by € -1.4 million to € -10.7 million (prior-year period: € -9.3 million).

The Biotest Group’s earnings after taxes improved to € 29.5 million in the first quarter of 2024 after € -20.4 million in the same quarter of the previous year due to the influencing factors described above. This results in earnings per ordinary share of € 0.74 after € -0.53 in the same period of the previous year.

One component of Biotest’s strategy is the continuous expansion of the company’s own plasma collection network in Europe. This is intended to ensure a sufficient supply of human blood plasma, the most important raw material for Biotest’s preparations. By the end of the first quarter of 2024, Biotest operated 37 plasma collection centres in Germany, Hungary and the Czech Republic. The opening of further plasma centres is planned for 2024. Another plasma collection centre was thus opened in Germany in April 2024. In addition, Biotest is participating financially in the establishment of further plasma centers with partners.

Following the approval of Yimmugo^® in Germany, Austria and the United Kingdom, Biotest is seeking approval for the attractive US target market. The approval process is already well advanced. In September 2023, the US Food and Drug Administration (FDA) informed Biotest that it accepted the Biologics License Application for Yimmugo^® with the indication Primary Immunodeficiencies for review. The FDA inspection of the Biotest Next Level facility took place in December 2023. Further steps to obtain the Biologics License Application for Yimmugo^® will be taken in the course of 2024.

With Fibrinogen concentrate and Trimodulin, two further new plasma proteins are in advanced development. Biotest successfully completed the Phase III trials for the use of Fibrinogen concentrate in the indications of congenital and acquired fibrinogen deficiency in February 2024, which represents an important milestone for the Biotest Next Level project at the Dreieich site. The first applications for marketing authorization are planned in the important markets in Europe and the USA.

Biotest has also started a Phase III trial with Trimodulin in the indication severe community-acquired pneumonia (sCAP). The first patient was treated with sCAP in an intensive care unit as part of the Phase III ESsCAPE study. In addition, the ongoing multinational TRICOVID trial was opened for the inclusion of patients with pneumonia caused by any type of pathogen and the first patient was treated as part of this expansion in December 2023. Biotest is also moving ahead with its research activities for existing products in order to improve patient care. We are striving for greater operational excellence in research and development as well as in procurement management and production. To this end, we will continue to focus on selected measures to make processes in all areas of the company even more efficient.

Outlook:

For the 2024 financial year, the Board of Management is aiming to increase revenue in the upper single-digit percentage range compared to 2023, taking into account the revenue from the technology disclosure and the development services for Grifols, S.A. This increase in revenue is possible due to the ramp-up of the Yimmugo^® production facility within Biotest Next Level.

Accordingly, the Board of Management expects an operating result (EBIT) in the range of € 80 to 100 million for 2024. As a result, the Board of Management expects a slightly improved return on capital employed (ROCE) in 2024 compared to the 2023 financial year and a positive cash flow from operating activities significantly above the previous year’s level.

The quarterly statement as of March 31, 2024 can be found on the company’s website at the following link Quarterly Reports (biotest.com).

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,600 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest is part of the Grifols Group, Barcelona, Spain (www.grifols.com).

Biotest AG will now also be publishing official press releases via X. You can find us at: https://twitter.com/BiotestAG

IR contact

Dr Monika Baumann (Buttkereit)

Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

Press release

Medios AG records further revenue growth in the first quarter of 2024 and confirms full-year guidance

• Revenue increases by 5.8% to €456.2 million in the first quarter
• Cash flow from operating activities increases to €43.4 million
• Closing of the Ceban acquisition planned for May 2024
• Guidance 2024 confirmed: Significant increase in revenue and margin expected

Berlin, May 7, 2024 – Medios AG (“Medios”), the leading provider of Specialty Pharma solutions in Germany, confirms its guidance for the 2024 financial year after a solid first quarter. Revenue increased by 5.8% year-on-year to €456.2 million in the period from January to March 2024 (previous year: €431.2 million). At €15.1 million (previous year: €15.0 million), EBITDA pre¹ reached the level of the same quarter of the previous year. As a result, the EBITDA pre¹ margin of 3.3% (previous year: 3.5%) was slightly lower than in the same period of the previous year. Cash flow from operating activities improved significantly in the first quarter of 2024 to €43.4 million (previous year:
€–25.3 million).

Heterogeneous sales and earnings development in the operating segments

The Pharmaceutical Supply segment achieved an increase in revenue of 8.9% to €401.0 million in the first quarter of 2024 (previous year: €368.1 million). The segment’s EBITDA pre¹ increased by 9.0% to €11.0 million (previous year: €10.1 million).

The Patient-Specific Therapies segment generated revenue of €55.1 million in the first quarter of 2024 after €62.9 million in the previous year. Around €3.5 million of this decline was attributable to the sale of Kölsche Blister GmbH in June 2023. In addition, regulatory price adjustments in some compounding areas still had a negative impact on the earnings development. As a result, the segment’s EBITDA pre¹ decreased by 9.4% to €5.9 million (previous year: €6.6 million).

Matthias Gaertner, Chief Executive Officer (CEO) of Medios AG: “In the first quarter of 2024, we once again achieved an increase in revenue and significantly increased our cash flow – despite the focus on the acquisition of Ceban, which we expect to successfully complete shortly. With an even larger Medios Group, which will also operate internationally for the first time, we expect to continue our successful growth trajectory for the rest of the 2024 financial year.”

In the first quarter of 2024, Medios announced the acquisition of Ceban Pharmaceuticals B.V. (“Ceban”). Ceban is the Dutch market leader in pharmaceutical compounding services and is also active in Belgium and Spain. In 2023, Ceban generated revenue of approximately €160 million and an adjusted EBITDA of approximately €29 million, which corresponds to an adjusted EBITDA margin of around 18%. The acquisition represents an important step in Medios’ growth strategy, which aims to build the leading European Specialty Pharma platform.

Positive outlook

Medios confirms the guidance for the 2024 financial year first announced on March 18, 2024. The company expects revenue of €1.9 billion to €2.1 billion and EBITDA pre¹ of €82 million to €91 million. This expectation is based on the assumption that the acquisition of Ceban Pharmaceuticals B.V. will be completed shortly and fully consolidated from the beginning of May 2024.

In the medium term, the market share in the area of patient-specific therapies in particular is to be further expanded, thereby increasing the profitability of the entire Medios Group. Accordingly, Medios is aiming for consolidated revenue of more than €2bn and an EBITDA pre¹ margin at least in the mid-single-digit range in the medium term.

Important dates for Medios AG in the 2024 financial year

June 6 to 7:  Warburg Highlights – Hamburg

August 13:  Half-Year Financial Report 2024

August 14:  Annual General Meeting 2024

September  25: Berenberg and Goldman Sachs 13th German Corporate

Conference – Munich

November 12: Quarterly statement as of September 30, 2024

Medios AG’s quarterly statement as of March 31, 2024 is available for download on the Investor Relations website.

——————-

About Medios AG

Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.

Medios AG is Germany’s first listed specialty pharmaceutical company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

www.medios.ag

Contact

Claudia Nickolaus

Head of Investor & Public Relations, ESG Communications

Medios AG

Heidestraße 9 | 10557 Berlin

T +49 30 232 566 800

c.nickolaus@medios.ag

www.medios.ag

Disclaimer

This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.

Berlin, May 6, 2024 – The Supervisory Board of Medios AG (“Medios”) has appointed Constantijn van Rietschoten as member to the Company’s Executive Board with effect from May 1, 2024. In his new role as Chief International Markets, van Rietschoten, who had previously been Head of International Business Development at Medios since April 2023, will assume responsibility for the entire international business and its further development. He has been appointed for a three year term, expiring on April 30, 2027.

Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG: “The European Specialty Pharma market offers great potential. We are therefore very pleased to welcome Constantijn van Rietschoten as Executive Board Member for International Markets. His outstanding expertise and international experience will be of great value for Medios’ international growth ambitions, which are now also reflected in the internationalization of the Company’s Executive Board. We wish him every success in his new role.”

Constantijn van Rietschoten, Executive Board Member at Medios AG: “Medios is a highly interesting company with a rapid development – recently also beyond the German borders following the acquisition of the Dutch market leader Ceban. I am delighted to contribute to the further internationalization of Medios and the development of a leading European Specialty Pharma platform.“

Prior to joining Medios in April 2023, van Rietschoten worked for Fagron for over 14 years. As member of the Executive Leadership Team, he held positions of Chief Marketing Officer, Chief Corporate Affairs Officer, and most recently as Area Leader EMEA. Van Rietschoten studied Public Administration at Erasmus University Rotterdam (the Netherlands).

Important dates for Medios AG in the 2024 financial year

May 7:                        Quarterly statement as at March 31, 2024
June 6 to 7:                Warburg Highlights – Hamburg
August 13:                 Half-Year-Financial Report 2024
August 14:                 Annual General Meeting 2024
September 25:          Berenberg and Goldman Sachs 13th German Corporate
Conference – Munich
November 12:           Quarterly statement as of September 30, 2024

——————-

About Medios AG
Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.

Medios AG is Germany’s first listed specialty pharmaceutical company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

www.medios.ag

Contact
Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
c.nickolaus@medios.ag
www.medios.ag

Disclaimer
This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.

https://ir-corporate.docmorris.com/en/investor-relations/convertible-bonds-2024
 

Frauenfeld, 2 May 2024

Press release

Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich

• The shareholders approved the annual report and consolidated and statutory financial statements for 2023 and the Board of Directors’ proposal for the appropriation of the balance sheet result 2023.
• Discharge was granted to all members of the Board of Directors and the Executive Board.
• All members of the Board of Directors and the Nomination and Compensation Committee were confirmed for a further term of office until the next Annual General Meeting.
• Amendments to the Articles of Association: The amendments to the provisions in line with the new company law and the main proposal to adjust the threshold for placing an item on the agenda were approved. The additions to the article in the Articles of Association on conditional share capital for financing, acquisitions and other purposes were also approved.
• Buis Bürgi AG as independent proxy and Ernst & Young AG as auditors were re-elected.
• The Annual General Meeting approved the Sustainability Report 2023.
• The shareholders also approved the compensation for the Board of Directors and the Executive Board. Mainly based on the recommendations of a proxy advisor who had already criticised the transparency of the compensation system prior to the Annual General Meeting, the 2023 Compensation Report was rejected in a consultative vote. DocMorris will examine this criticism in detail and seek dialogue on this topic with larger shareholders in order to present a Compensation Report next year that is widely accepted.

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

DocMorris

The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. The company was renamed from Zur Rose Group AG to DocMorris AG in May 2023 after the Swiss business was sold to Migros/Medbase. Excluding the Swiss business, about 1,600 employees in Germany, the Netherlands, Spain, France and Switzerland generated an external revenue of CHF 1,038 million serving over 9 million active customers in 2023. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

MEDICLIN: Transfer of operations of Reha-Klinik am Sendesaal to MEDICLIN took place on 1 May

Offenburg, 2 May 2024: On 1 May, the operation of the Reha-Klinik am Sendesaal was transferred to MEDICLIN.

A symbolic handover of the key between MEDICLIN COO Thomas Piefke, clinic managing director and regional managing director Holger Kammann and Heinz Beekmann, managing director of the Specht Group, took place on Monday. Beekmann presented the “Bremen Key” made of acrylic glass to the MEDICLIN representatives in front of the rehabilitation clinic.

At the beginning of April, representatives of MEDICLIN and the Specht Group signed the purchase agreement for the clinic. The clinic will now operate under the name “MEDICLIN Reha-Klinik am Sendesaal”.

“We extend a warm welcome to the employees in Bremen,” says MEDICLIN CEO Dr Joachim Ramming. “MEDICLIN has facilities throughout Germany in various areas – rehabilitation, acute care, nursing care, MVZs – but our core competence is and remains rehabilitation.”

Piefke adds: “We want to continue to grow in the rehabilitation sector, both inpatient and outpatient. We are delighted that the Reha-Klinik am Sendesaal is now part of the MEDICLIN family!” 

For further information:

MEDICLIN Aktiengesellschaft
Okenstrasse 27
77652 Offenburg
Germany

Investor Relations
Ender Gülcan
Phone: 0781/488-326
ender.guelcan@mediclin.de

Public Relations
Dr Janina Lossen
Phone: 0781/488-180
janina.lossen@mediclin.de

www.mediclin.de

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 32 clinics, six care facilities and ten medical care centers. The Group has around 8,300 beds/care places and employs around 10,000 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group